AI, machine learning offer hope for speeding Alzheimer's development

"Unlearn.AI Inc., of San Francisco, has developed a process to create digital twins of Alzheimer's disease patients in the active-treatment group that predict how they would perform if they weren't given drug. The company's Digenesis process uses historical clinical trial datasets from patients who participated in the control arms of clinical trials to create the twins who are a mash-up of multiple patients in the studies."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

How will AI transform the future of medicine?

White Papers

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs

Both methods reduce control arm sizes, but only digital twins control for bias.
A Phase 2 study on crenezumab in mild-to-moderate AD was used to retrospectively assess the validity of Unlearn's approach for AD clinical trials.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.